← All peptides
Healing & Recovery
Preclinical

PTD-DBM

Also known as: PTD-DBM

PTD-DBM is a cell-permeable peptide studied in hair-loss research for its ability to activate Wnt/beta-catenin signaling and promote hair follicle neogenesis.

Last updated

Mechanism of Action

PTD-DBM links a protein transduction domain (PTD) to a Dishevelled-binding motif (DBM) that disrupts the interaction between CXXC5 and Dishevelled. CXXC5 is a negative feedback regulator of the Wnt/beta-catenin pathway; by blocking its binding to Dishevelled, PTD-DBM relieves this inhibition and restores active Wnt signaling. Elevated beta-catenin activity then drives hair follicle stem cell activation and wound-induced hair follicle neogenesis in animal models.

Half-life
Not well characterized; topical and locally acting
Administration Routes
topical
Research Status
Preclinical

Reported Benefits

  • Activates Wnt/beta-catenin signaling in research models
  • Studied for hair follicle regeneration and neogenesis
  • Investigated for promoting hair regrowth
  • Often paired with valproic acid in studies for additive Wnt activation
  • Explored for wound-induced follicle formation

Potential Side Effects

  • Possible local skin irritation
  • Limited human safety data
  • Theoretical concern with chronic Wnt pathway activation
  • Unknown long-term effects

Common Dosing

For research use only; preclinical work applies it topically to the scalp/skin, frequently combined with valproic acid as a Wnt enhancer. No validated human dosing exists and this is not medical advice.

The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.

Contraindications

  • Not for human or clinical use
  • Application to broken skin or active skin cancer (Wnt activation concern)
  • Pregnancy or breastfeeding

No documented stacking partners for PTD-DBM yet.

  • Targeting of CXXC5 by a Competing Peptide Stimulates Hair Regrowth and Wound-Induced Hair Neogenesis

    2017

    View
  • The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing

    2015

    View
  • CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD(2)

    2023

    View
  • Adhesive Hydrogel Patch-Mediated Combination Drug Therapy Induces Regenerative Wound Healing through Reconstruction of Regenerative Microenvironment.

    2023

    View

It blocks CXXC5 from suppressing the Wnt/beta-catenin pathway, which in animal studies reactivates hair follicle stem cells and promotes new follicle formation.

No. Evidence is from preclinical and animal research; it is an experimental research compound, not an approved hair-loss treatment.

PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.